Driving Inclusivity, Validity, and Equity in Research Through Strategic Engagement (DIVERSE)
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The purpose of this research study is to enhance inclusion and diversity in clinical trial enrollment by training participants to perform and provide feedback through a community-based protocol review process, called DIVERSE.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek 18 lat lub więcej
- •Płynna znajomość języka angielskiego
- •Umiejętność zrozumienia i wyrażenia zgody ustnej
- •Pacjent ośrodka DFCI, który nie ma objawów białaczki przez ponad rok
✗ Disqualifies
- •Osoby niezdolne do wyrażenia zgody
- •Osoby poniżej 18 lat
- •Osoby pozbawiające wolności
- •Osoby niechętne lub niezdolne do zachowania poufności materiałów badawczych
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 16, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
Dana-Farber Cancer Institute
Boston, United States
Trial contact
Andrew Hantel, MD
Oldy S Bejarano, MPH
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/17/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.